Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PLx Pharma has received $565,449 for the first year of a potential two-year $1,118,398 grant to carry out research designed to develop a treatment for premature babies with a congenital heart defect.
Subscribe to our email newsletter
The grant is from the Eunice Kennedy Shriver National Institute of Child Health & Human Development.
PLx Pharma and UTHealth are working to reduce the GI toxicity of NSAIDs by formulating this family of drugs with a natural lipid named phosphatidylcholine.
PLx Pharma president Ron Zimmerman said the product is being developed to meet a serious unmet need for the compelling patient population.